Skip to main content

Table 4 Subjective self-assessment

From: Lidocaine for systemic sclerosis: a double-blind randomized clinical trial

  Placebo group, n % Lidocaine group, n % P-value
Improvement of oral cavity opening 6 (50%) 7 (58.3%) 0.682*
Improvement of skin pigmentation 8 (66.7%) 7 (58.3%) 0.673*
Improvement of skin thickening 12 (100%) 12 (100%) 1.00
Improvement of gastroesophageal complaints 5 (41.7%) 8 (66.7%) 0.219*
Improvement of joint pain 5 (41.7%) 7 (58.3%) 0.414*
The biggest drawback to trial participation    
None 4 (33.3%) 4 (33.3%) 1.00
Oesophageal manometry 8 (66.7%) 8 (66.7%)  
Would like to continue receiving treatment 12 (100%) 12 (100%) 1.00
  1. * Chi-square test